Avanir Pharmaceuticals Inc (AVNR) Financial Statements (2024 and earlier)

Company Profile

Business Address 20 ENTERPRISE
ALISO VIEJO, CA 92656
State of Incorp. DE
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2014
9/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments55,259
Cash and cash equivalents55,259
Receivables12,526
Inventory, net of allowances, customer advances and progress billings710
Inventory710
Prepaid expense1,391
Other current assets991
Other undisclosed current assets966
Total current assets:71,844
Noncurrent Assets
Inventory, Noncurrent784
Property, plant and equipment1,593
Restricted cash and investments1,304
Other noncurrent assets554
Total noncurrent assets:4,235
TOTAL ASSETS:76,079
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities25,561
Employee-related liabilities7,776
Accounts payable5,876
Accrued liabilities11,909
Debt 7,943
Other undisclosed current liabilities 1,289
Total current liabilities:34,792
Noncurrent Liabilities
Long-term debt and lease obligation 21,422
Long-term debt, excluding current maturities 21,422
Liabilities, other than long-term debt1,393
Other liabilities1,393
Total noncurrent liabilities:22,815
Total liabilities:57,607
Equity
Equity, attributable to parent18,472
Common stock15
Additional paid in capital518,992
Accumulated deficit(500,536)
Total equity:18,472
TOTAL LIABILITIES AND EQUITY:76,079

Income Statement (P&L) ($ in thousands)

9/30/2014
9/30/2013
Revenues
(Revenue, Net)
75,366
Cost of revenue
(Cost of Goods and Services Sold)
(4,150)
Gross profit:71,216
Operating expenses(146,793)
Other undisclosed operating income4,150
Operating loss:(71,427)
Nonoperating income52
Investment income, nonoperating52
Other nonoperating expense(0)
Interest and debt expense(4,098)
Loss from continuing operations before income taxes:(75,473)
Income tax expense(3)
Loss from continuing operations:(75,476)
Loss before gain (loss) on sale of properties:(75,476)
Net loss available to common stockholders, diluted:(75,476)

Comprehensive Income ($ in thousands)

9/30/2014
9/30/2013
Net loss:(75,476)
Comprehensive loss, net of tax, attributable to parent:(75,476)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: